Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > short positions

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Feb 06, 2021 1:02pm

160 Views

Post# 32493236

RE:RE:RE:RE:RE:RE:RE:RE:short positions

I have heard two claims about the offering, neither directly from the company. One was that three institutions took 60% of the deal and the other was that there were 15-20 institutions involved in it. Both claims could potentially be true. I know that at one of the brokers involved, retail got only asmall slice of the deal, so the 90% institutional number could also be right.